{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T13:12:20Z","timestamp":1755695540092,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10792-021-02004-8","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T07:04:06Z","timestamp":1629443046000},"page":"95-101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment outcomes of combination of anti-vascular endothelial growth factor injection and laser photocoagulation in Type 1 ROP and APROP"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2256-9380","authenticated-orcid":false,"given":"Parveen","family":"Sen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi Ashok Kumar","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramod","family":"Bhende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suganeswari","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"issue":"1","key":"2004_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/s1091-8531(99)70091-1","volume":"3","author":"PG Steinkuller","year":"1999","unstructured":"Steinkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK (1999) Childhood blindness. J AAPOS 3(1):26\u201332. https:\/\/doi.org\/10.1016\/s1091-8531(99)70091-1","journal-title":"J AAPOS"},{"issue":"7","key":"2004_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) BEAT-ROP Cooperative group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364(7):603\u2013615. https:\/\/doi.org\/10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"issue":"7","key":"2004_CR3","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/01.iae.0000244285.79004.e6","volume":"26","author":"A Kychenthal","year":"2006","unstructured":"Kychenthal A, Dorta P, Katz X (2006) Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina 26(7):S11\u2013S15. https:\/\/doi.org\/10.1097\/01.iae.0000244285.79004.e6","journal-title":"Retina"},{"issue":"12","key":"2004_CR4","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","volume":"100","author":"AL H\u00e5rd","year":"2011","unstructured":"H\u00e5rd AL, Hellstr\u00f6m A (2011) On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment: a review. Acta Paediatr 100(12):1523\u20131527. https:\/\/doi.org\/10.1111\/j.1651-2227.2011.02445.x","journal-title":"Acta Paediatr"},{"issue":"1","key":"2004_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jaapos.2011.11.002","volume":"16","author":"RL Avery","year":"2012","unstructured":"Avery RL (2012) Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS 16(1):2\u20134. https:\/\/doi.org\/10.1016\/j.jaapos.2011.11.002","journal-title":"J AAPOS"},{"issue":"4","key":"2004_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.tjo.2012.11.002","volume":"2","author":"CH Yang","year":"2012","unstructured":"Yang CH (2012) Anti-vascular endothelium growth factor therapy for retinopathy of prematurity: a continuing debate. Taiwan J Ophthalmol 2(4):115\u2013116","journal-title":"Taiwan J Ophthalmol"},{"issue":"8","key":"2004_CR7","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130(8):1000\u20131006. https:\/\/doi.org\/10.1001\/archophthalmol.2012.592","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"2004_CR8","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","volume":"245","author":"EJ Chung","year":"2007","unstructured":"Chung EJ, Kim JH, Ahn HS, Koh HJ (2007) Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 245(11):1727\u20131730. https:\/\/doi.org\/10.1007\/s00417-007-0661-y","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"2004_CR9","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00417-010-1375-0","volume":"248","author":"JY Lee","year":"2010","unstructured":"Lee JY, Chae JB, Yang SJ, Yoon YH, Kim JG (2010) Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol 248(9):1257\u20131262. https:\/\/doi.org\/10.1007\/s00417-010-1375-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"2004_CR10","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ophtha.2007.08.050","volume":"115","author":"K Sonmez","year":"2008","unstructured":"Sonmez K, Drenser KA, Capone A Jr, Trese MT (2008) Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 115(6):1065\u20131070. https:\/\/doi.org\/10.1016\/j.ophtha.2007.08.050","journal-title":"Ophthalmology"},{"issue":"12","key":"2004_CR11","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121(12):1684\u20131694. https:\/\/doi.org\/10.1001\/archopht.121.12.1684","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"2004_CR12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1395-3907.2003.00171.x","volume":"81","author":"M O'Keefe","year":"2003","unstructured":"O\u2019Keefe M, Lanigan B, Long VW (2003) Outcome of zone 1 retinopathy of prematurity. Acta Ophthalmol Scand 81(6):614\u2013616. https:\/\/doi.org\/10.1111\/j.1395-3907.2003.00171.x","journal-title":"Acta Ophthalmol Scand"},{"issue":"5","key":"2004_CR13","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114(5):855\u2013859. https:\/\/doi.org\/10.1016\/j.ophtha.2007.01.017","journal-title":"Ophthalmology"},{"issue":"1","key":"2004_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4103\/0301-4738.29505","volume":"55","author":"PK Shah","year":"2007","unstructured":"Shah PK, Narendran V,\u00a0Tawansy KA, Raghuram A, Narendran K (2007) Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 55(1):75. https:\/\/doi.org\/10.4103\/0301-4738.29505","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"2004_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3928\/15428877-20070501-09","volume":"38","author":"A Travassos","year":"2007","unstructured":"Travassos A, Teixeira S, Ferreira P, Regadas I, Travassos AS, Esperancinha FE, Prieto I, Pires G, van Velze R, Valido A, Machado Mdo C (2007) Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthal Surg Lasers Imag 38(3):233\u20137. https:\/\/doi.org\/10.3928\/15428877-20070501-09","journal-title":"Ophthal Surg Lasers Imag"},{"issue":"6","key":"2004_CR16","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","volume":"28","author":"HA Mintz-Hittner","year":"2008","unstructured":"Mintz-Hittner HA, Kuffel RR Jr (2008) Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 28(6):831\u2013838. https:\/\/doi.org\/10.1097\/IAE.0b013e318177f934","journal-title":"Retina"},{"issue":"3 Suppl","key":"2004_CR17","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","volume":"28","author":"H Quiroz-Mercado","year":"2008","unstructured":"Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV (2008) Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 28(3 Suppl):S19-25. https:\/\/doi.org\/10.1097\/IAE.0b013e318159ec6b","journal-title":"Retina"},{"issue":"3 Suppl","key":"2004_CR18","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","volume":"28","author":"GA Lalwani","year":"2008","unstructured":"Lalwani GA, Berrocal AM, Murray TG, Buch M, Cardone S, Hess D, Johnson RA, Puliafito CA (2008) Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 28(3 Suppl):S13\u2013S18. https:\/\/doi.org\/10.1097\/IAE.0b013e3181644ad2","journal-title":"Retina"},{"issue":"10208","key":"2004_CR19","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, Li J, Liew M, Maier R, Zhu Q, Marlow N (2019) Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet 394(10208):1551\u20131559. https:\/\/doi.org\/10.1016\/S0140-6736(19)31344-3","journal-title":"Lancet"},{"issue":"1","key":"2004_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1046\/j.1442-9071.2000.00226.x","volume":"28","author":"HL Naug","year":"2000","unstructured":"Naug HL, Browning J, Gole GA, Gob\u00e9 G (2000) Vitreal macrophages express vascular endothelial growth factor in oxygen-induced retinopathy. Clin Exp Ophthalmol 28(1):48\u201352. https:\/\/doi.org\/10.1046\/j.1442-9071.2000.00226.x","journal-title":"Clin Exp Ophthalmol"},{"issue":"1","key":"2004_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ajo.2006.02.018","volume":"142","author":"JT Flynn","year":"2006","unstructured":"Flynn JT, Chan-Ling T (2006) Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease. Am J Ophthalmol 142(1):46\u201359. https:\/\/doi.org\/10.1016\/j.ajo.2006.02.018","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"2004_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.5301\/ejo.5000176","volume":"22","author":"HA Mintz-Hittner","year":"2012","unstructured":"Mintz-Hittner HA (2012) Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial. Eur J Ophthalmol 22(5):685\u20136. https:\/\/doi.org\/10.5301\/ejo.5000176","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"2004_CR23","first-page":"29","volume":"68","author":"R Autrata","year":"2012","unstructured":"Autrata R, Senkov\u00e1 K, Holousov\u00e1 M, Krejc\u00edrov\u00e1 I, Dolezel Z, Borek I (2012) Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II\u2013four years results. Cesk Slov Oftalmol 68(1):29\u201336","journal-title":"Cesk Slov Oftalmol"},{"issue":"4","key":"2004_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4103\/tjo.tjo_62_18","volume":"9","author":"P Sen","year":"2019","unstructured":"Sen P, Abraham S, Jain S, Gopal L, Bhende P (2019) Treatment outcomes of zone 1 retinopathy of prematurity: a study from a tertiary eye care center in South India. Taiwan J Ophthalmol 9(4):255\u2013261. https:\/\/doi.org\/10.4103\/tjo.tjo_62_18","journal-title":"Taiwan J Ophthalmol"},{"issue":"10","key":"2004_CR25","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1097\/iae.0b013e31817f2f15","volume":"28","author":"MJ Kim","year":"2008","unstructured":"Kim MJ, Kim SJ, Yu YS (2008) The risk for retinal detachment associated with hemorrhages pre- and postlaser treatment in retinopathy of prematurity. Retina 28(10):1451\u20137. https:\/\/doi.org\/10.1097\/iae.0b013e31817f2f15","journal-title":"Retina"},{"issue":"4","key":"2004_CR26","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ajo.2006.05.048","volume":"142","author":"N Azuma","year":"2006","unstructured":"Azuma N, Ishikawa K, Hama Y, Hiraoka M, Suzuki Y, Nishina S (2006) Early vitreous surgery for aggressive posterior retinopathy of prematurity. Am J Ophthalmol 142(4):636\u2013643. https:\/\/doi.org\/10.1016\/j.ajo.2006.05.048","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"2004_CR27","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1177\/112067210701700516","volume":"17","author":"T Micelli Ferrari","year":"2007","unstructured":"Micelli Ferrari T, Furino C, Lorusso VV, Dammacco R, Sborgia G, Sborgia L, Besozzi G (2007) Three-port lens-sparing vitrectomy for aggressive posterior retinopathy of prematurity: early surgery before tractional retinal detachment appearance. Eur J Ophthalmol 17(5):785\u20139. https:\/\/doi.org\/10.1177\/112067210701700516","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"2004_CR28","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/s0002-9394(03)00190-9","volume":"136","author":"KA Hutcheson","year":"2003","unstructured":"Hutcheson KA, Nguyen AT, Preslan MW, Ellish NJ, Steidl SM (2003) Vitreous hemorrhage in patients with high-risk retinopathy of prematurity. Am J Ophthalmol 136(2):258\u2013263. https:\/\/doi.org\/10.1016\/s0002-9394(03)00190-9","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"2004_CR29","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.3109\/14767058.2012.684109","volume":"25","author":"C Dani","year":"2012","unstructured":"Dani C, Frosini S, Fortunato P, Bertini G, Pratesi S, Pollazzi L, Caputo R, La Torre A (2012) Intravitreal bevacizumab for retinopathy of prematurity as first line or rescue therapy with focal laser treatment. A case series. J Matern Fetal Neonatal Med. 25(11):2194\u20137. https:\/\/doi.org\/10.3109\/14767058.2012.684109","journal-title":"J Matern Fetal Neonatal Med."},{"issue":"22","key":"2004_CR30","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.12659\/msm.897095","volume":"10","author":"SD Nicoar\u0103","year":"2016","unstructured":"Nicoar\u0103 SD, Stef\u0103nu\u0163 AC, Nascutzy C, Zaharie GC, Toader LE, Drugan TC (2016) Regression rates following the treatment of aggressive posterior retinopathy of prematurity with bevacizumab versus laser: 8-year retrospective analysis. Med Sci Monit 10(22):1192\u20131209. https:\/\/doi.org\/10.12659\/msm.897095","journal-title":"Med Sci Monit"},{"issue":"2","key":"2004_CR31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4103\/0301-4738.128639","volume":"62","author":"G Sanghi","year":"2014","unstructured":"Sanghi G, Dogra MR, Katoch D, Gupta A (2014) Aggressive posterior retinopathy of prematurity in infants \u2265 1500 g birth weight. Indian J Ophthalmol 62(2):254\u2013257. https:\/\/doi.org\/10.4103\/0301-4738.128639","journal-title":"Indian J Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-02004-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-021-02004-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-02004-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T15:15:18Z","timestamp":1643642118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-021-02004-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2004"],"URL":"https:\/\/doi.org\/10.1007\/s10792-021-02004-8","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"type":"print","value":"0165-5701"},{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"24 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was waived by the local Ethics Committee of the Medical Research Foundation, Chennai, in view of the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the parents.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}